tl;dr: Researchers at La Jolla Institute, Scripps Research, and IAVI developed an HIV vaccine using a "germline targeting" approach that trains naive B cells through a priming shot and sequential boosters to produce rare broadly neutralizing antibodies. In rhesus macaque trials, roughly 44% of animals generated these antibodies at high levels — the strongest such response recorded in primates. The priming immunogen is already in Phase 1 human trials (IAVI G004), with plans to test the full regimen in humans next.